Note: MDPTs - multidisciplinary prescribing teams
Page numbers in *italics* refer to figures, whilst those in **bold** refer to tables.

abbreviations in prescriptions 55–56, **57**
abdomen, quadrants **228**
abdominal examination 221–222, 226, **227–228**
abortions 254
absorption of drugs 149, 151, 151–152
   breastfeeding and 256
   children/young people 262–263
dosage forms 152
liver disease 243
older people 258
pregnancy **252**
   renal impairment 248
routes 151, 151–152, 152–153
Access to Health Records Act (1990) **75**
Access to Medical Reports Act (1988) **75**
accident and emergency department 311
accidents 261
accountability 40, 117, 288
acetylcholine 160
   receptors 157, 158
acetylcholinesterase inhibitors 160
Act of Parliament 47, 48, 88
actus reus 49
acute care, prescribing errors 285
adherence 176, 260
   see also concordance
administration routes of drugs 151, 151–152,
   152–153
   breastfeeding 256
   children 262–263, 265
   see also side effects
   advertising by drug companies 105, 106–107
   Advisory Committee on Borderline Substances (ACBS) 54
   advocacy 72–73, 267
   affinity 156

Adults with Incapacity (Scotland) Act (2000) 71–72
advance directives 72, 73, 80
adverse drug reactions (ADRs) 149, 170
   breastfeeding 172, 255, 256
   cessation 173
   children 265
   consequences 170, 171
   costs relating to 149
   disease states 171, 172
   ethnicity 172
   gender 172
   influencing factors 171–172
   liver impairment 171
   management and avoidance 169–174
   MHRA e-learning 174
   MHRA monitoring 38
   multiple drug therapy 171–172
   older people 171, 172, 258
   renal impairment 171
   reporting 173
   side effects vs 170
   steps to determine cause 172–173
   unlicensed medicines 54
   see also side effects
   Access to Health Records Act (1990) **75**
   Access to Medical Reports Act (1988) **75**
   accountability 40, 117, 288
   acetylcholine 160
      receptors 157, 158
   acetylcholinesterase inhibitors 160
   Act of Parliament 47, 48, 88
   actus reus 49
   acute care, prescribing errors 285
   adherence 176, 260
      see also concordance
   administration routes of drugs 151, 151–152,
      152–153
      breastfeeding 256
      children 262–263, 265
      see also side effects
      advertising by drug companies 105, 106–107
      Advisory Committee on Borderline Substances (ACBS) 54
      advocacy 72–73, 267
      affinity 156
age
  breathing rates 208, 208
  childhood stages 262
  pulse rate 212
  renal function decline 166, 167, 258
  see also older people
ageing workforce 286–287
agonists 156–157, 157
Airedale NHS Trust v Bland (1993) 82
albumin 242, 248
alcohol 167, 256
allergies 131, 172
‘allied health professional prescriber’ 2
allied health professionals 24–27
  accountability and responsibility 40
  benefits of prescribing 90
  educational programmes 29
  independent prescribing 190
  MDPTs 190
  negligence and duty of care 51
  number 279
  prescribing history 278
  professional code of practice 39, 39
  supplementary prescribing 190
  training 190
Allied Health Professions Medicines Project 25
Alzheimer’s disease 72
angiotensin-converting enzyme (ACE) inhibitors 160, 171, 249
angiotensin II 160
annual development review 291
antagonists 157, 158, 167
antibiotics 211
antidepressants 159, 170, 245, 259
antihistamines 158, 245, 246
antihypertensives 163, 167, 168
antimuscarinic drugs 158, 170
antipsychotics 245
apex beat 212
appraisal 297–298
Area Prescribing Committee (APC) 298
arthritis 193
  case studies 173, 306
ascites 244, 245
assessment(s)
  breathing 207–209
  independent prescribing 12–14
  mental capacity 58, 68–69
  pain in children 215
  renal function 247–248
  of risk 76–77
Association of the British Pharmaceutical Industry (ABPI) 105, 106
asthma 150, 170, 208, 209, 210
  case study 308
  remote prescribing 44
attitude shifts 3–4
audit of practice 292
auditory acuity 219
auscultation 217
abdomen 227
respiratory system 224
autonomy 58–77, 69
  definition 59–61, 79
  deontology and 65
  informed consent and 63–64, 65, 66
  Kantian view 60, 66
  media influence 107
  respect for 79
  uninformed consent 63–64
  young people 69
AVPU scale 206, 207, 207
B (Ms) v An NHS Trust (2002) 67
Balint’s consultation model 124
Battle’s sign 219
behaviour, health beliefs and 101
bendroflumethiazide 168
beneficence 79
benefits, non-medical prescribing 3, 4, 13, 89–90, 185–188, 283
benzodiazepines 158, 167
Berne’s model of consultation 125
‘best interest’ decision/principle 59, 68, 72, 73, 80–81
  autonomy and 60, 61
  children and 65, 69, 70
beta blockers 150, 158
bilirubin 242
bioavailability 152–153
  liver disease 243–244
  renal impairment 248
biomechanics 193
black and minority ethnic (BME) groups 269–271, 270
bleeding risk, drugs increasing 245, 245
blood clotting, reduced, in liver disease 242, 245
blood pressure 213
  elevated see hypertension
  measurement 213, 213, 214
body language 119, 120
body surface area (BSA) 247, 263
Bolam test 50–51
Bolam v Friern Hospital Management Committee (1957) 50–51
borderline substances 54
Botox® 9, 44
bowel sounds 227
brachial artery, pulse 212
Bradshaw’s Taxonomy of Needs (1972) 10
bradycardia 212
bradypnoea 208
breastfeeding 255–257
case study 169, 308
holistic approach 257
prescribing considerations 257
breast milk 255–256, 257
case studies xvii
calculation skills 234, 235
Caldicott guardians 74
Calgary–Cambridge guide model (Kurtz) 116, 125, 126
Canada 281
capacity see mental capacity
captopril 160
carbamazepine 172
care homes 58, 236
Care Quality Commission (CQC) 58, 289, 290
Care Quality Commission (Registration) Regulations (2009) 289
care regulators 45, 45
carotid artery 212
carrier molecules 157, 159
effects of drug action 161–162
case law 47, 64
table of cases 84
case studies xvii
health professional 23–24, 310–314
independent prescribing 24, 25
MDPTs 199, 313
patient 305–309
supplementary prescribing 23–24
V100, V150, V300 20, 21, 22
Cerebral vascular disease 261
Chatterton v Gerson (1981) 64
chemotherapy, MDPT for 196
Chester v Afshar (2005) 51, 65
Children Act (1989) 70, 268
Children Act (2004) 268
children and young people 20, 262–268
advocacy 73
administration of medicines to 268
autonomy 59, 61
capacity to consent 70
case studies 308
communication 122, 267
consent 65, 69–71
consultations 122, 123, 267
defined 262, 262
drugs licensed for 256
health beliefs, health profile 267
history taking 266–267
holistic approach to prescribing 266–268
licensing of drugs 264
mental health issues 267
pain assessment 215
podiatry 193
prescribing considerations 264, 265, 265, 268
professional responsibilities towards 266
pulse rate 212
safeguarding 268
school nurses and 20
transcribing for 46
unlicensed medicines 264
welfare and overriding lack of consent 70, 71
chiropodists see podiatrists
ciprofloxacin 164
civil claims 41
civil law 49, 49, 50
clarithromycin 171
Index

clinical audit 293
clinical commission group (CCG) 284
clinical decision-making (CDM) 138–144
  advance directives 72
  advocacy 73
  autonomy and 60–61, 69
  ‘best interest’ see ‘best interest’ decision/principle
  biases 143
  children 71, 72
  cognitive continuum 138–139, 141
  complexity 97
  consultations 114, 125, 126, 138–144
  dynamic nature of 138, 139–140, 143
  ethics 77, 78
  factors influencing 139, 143
  heuristics and intuition 141–142, 143
  hypothetical–deductive model 139–140, 141, 144
  independent prescribing 13–14
  legal issues 42
  medical and non-medical prescribers 138
  monitoring/follow-up 137
  numeracy 234
  paternalism 59, 60
  patient involvement 117, 176
  pattern recognition 140–141, 143, 144
  personal beliefs/preferences 91
  product choice and 104
  shared, informed consent and 66
  strategies 139, 143
  tort law and 50
clinical examination 135–136, 205, 216–218, 237
  abdominal 221–222, 226, 227–228
  ENT system 206, 218–220
  neurological 229–232
  principles 216–218
  respiratory system 220–221, 223–224
clinical governance 8, 40, 42, 288–293
  accountability 40, 288
  annual reports 288
  appraisal 297–298
  clinical audit 293
  CPD 294–297
  formularies strengthening 104
  framework 291–293
  introduction/background 288
  NHS Plan aims 290
  ‘as organisational conscience’ 290
  remote prescribing 45
  seven key pillars 288
  trust structures to support 288–289
clinical guidelines 294
clinical management plan (CMP) 15–17, 19, 136–137
  agreement on 16
  allied health professionals 17, 18, 19, 24–25
  case study 312
  consent 63, 71
  description and information included 15–16, 16
  handover, consultation model 125
  independent prescriber responsibility 15, 16
  limitations/problems affecting 284
  negotiation 117, 136
  nurses 17
  pharmacists 17, 23, 24
  review 17
  supplementary prescribing 15, 16–17, 18
  termination 17, 17
clinical negligence 41, 51
clinical practice changes 6–7
clinical reasoning see clinical decision-making (CDM)
clinical skills 136, 205–239
clinical supervision 292, 297
clinical trials 173, 264
‘close communication’ 108
clothing, reduced, in liver disease 242, 245
codeine 170, 172
codes of conduct 95
codes of practice 39, 39, 95
cognitive continuum 138–139, 141
collaborative working practice 200
commissioning, MDPTs and 197–199
Commissioning for Quality and Innovation (CQUIN) 290
common law 47
communication
  children/young people 122, 267
  MDPTs 108, 195, 195–196, 198
  therapeutic, consultations see therapeutic communication
community care 286
community nurses xiv, 21, 135
  ageing workforce and 286
  case study 311
  education needs 21
  impact of prescribing 284
Community Practitioner Nurse Prescriber Formulary 20, 162, 166
community practitioner nurses 20, 21, 90
co-morbidity 166
controlled drugs 53
formularies 20, 162, 166
influence on prescribing 89–90
transcribing 45
cO-morbidity 165–167
  case study 306
  narrow therapeutic index drugs 175
  pharmacology 165–166
  polypharmacy 166–167, 171–172
‘comparative need’ 10–11
compensation 51, 52
competence 20
  maintaining 296–297
  prescribing for children 266
competency framework 6, 296
compliance 136, 176
concordance 11, 103, 136, 175–176, 177
  older people 261
  patient influence on prescribing 176
conduct, professional standards 39, 39
confidence of prescribers 104
confidentiality 74–75, 75, 186
  children/young people 267–268
confusion, drugs causing 245
consent 58–77
  adults lacking mental capacity 65, 67–69, 71–72
  adults with mental capacity 62–66
  advance directives 72
  autonomy and 63–64, 65, 66, 79
  avoiding litigation 76, 76–77
  children 20, 65, 69–71
  complexity of obtaining 64, 65
  definition 61
  England, Wales, Scotland, N. Ireland 71–72
  explicit (‘express’) verbal 62
  explicit (‘express’) written 63
  ‘Fraser competent’/guidelines 70
  ‘Gillick competent’ 70
  implied 62
  importance 61–77
  information for 66
  informed 63–66
  lasting power of attorney (LPA) 71–72
  mental capacity to/for 61, 62–66
  ‘misinformed’ 66
  non-verbal 62
  parents 70
  remote prescribing 44
  school nurses 20
side effects and 64
standards of disclosure for 65
‘un-informed’ 63, 64
withdrawal 64–65
young people (16,17 years) 69, 70
consequentialism 78
consultations 96–97, 98, 113–147
  children 122, 123, 267
  clinical decision-making 125, 126, 138–144
  communication in see therapeutic communication conclusion 137
definitions/use of term 114
as dynamic journey 125
effective 113–147
health beliefs and 101
influence on prescribing 96–97, 98
models 114, 116, 124–126
older people 122, 124
parts of 121
patient expectations 97–98
patient satisfaction 283
time, organisational issues 94–95, 283, 284
time before collecting patient 121–122
young people 122
consultation umbrella 113, 114–115, 115, 126–138, 139, 144
consultation conclusion 137
follow-up 137
history taking see history taking
  physical examination 135–136
  plan/treatment 136–137
  tests and investigations 136
consumers, patients as 98–99
contact professional of MDPT 199
continuing professional development (CPD) 186–187, 294–296, 298
consultations 30–31, 83, 110, 145, 180, 202, 238–239, 272, 294, 299
evidence-based resources 295
funding 95–96
importance 295, 296
maintaining competency and 296–297
MDPTs 186–187
methods/ways of achieving 295
provision 292
take-up 296
continuity of care 94
contraception 244, 245
controlled drugs 38

allied health professionals 18, 25, 53

legal issues 43, 46, 58

nurses 22, 53

pharmacists 23, 24, 53

prescribing 58

prescribing rights 53

stolen prescription forms 46

supplementary prescribing 18, 23, 25

transcribing and 46

V300 prescribing 22

core themes, in book xv

core values (six) 7

coronary heart disease 261

Coroners Act (1988) 81

cosmetic injectables 9, 44–45

cost-effectiveness 7, 8, 103, 199

MDPTs 199

PACT data 284, 294

product choice/formularies 103, 174, 294, 298

courts 48

cranial nerve examination 229, 230

checklist 231–232

creatinine clearance (CrCl) 247

crime and criminal law 49, 49

criminal behaviour 43


6 Cs 7

culture

influencing prescribing 99–101

organisational 93

current health, in history taking 129

current practices 277–278

customary law 47

cyclosporin 174

cytochrome P450 enzymes 154, 154, 175

Darzi review 200

data protection 74–75, 75

Data Protection Act (1998) 75

death, doctrine of double effect 81–82

decision-making see clinical decision-making (CDM)

deep tendon reflexes 229, 233

definition, non-medical prescribing 2

dementia 72, 261

dentists 15, 27, 37, 44, 52

deontology 65, 78

Department of Health (DH) 6, 67–68, 74–75

Operating Framework 6

‘dependent prescribing’ 14

depression 246

case study 307

dermatology services 283, 310

diabetes 44, 168

case studies 305, 314

diabetic neuropathy 164

diagnosis 126, 135, 280

diarrhoea 150, 152, 170, 248

diastolic pressure 213

diethylstilbestrol 251

digoxin 171, 174, 175

disclosure of information 65, 74

dispensing errors 76

disposal of medicines 260

distribution of drugs 20, 153, 167

children/young people 263

liver disease 244

older people 258

pregnancy 252

renal impairment 248

district nurses xiv, 20, 277

benefits of prescribing 90

changing roles 21

MDPTs 194

diuretics 259

doctors

impact of non-medical prescribing 282

junior 4, 6

prescribing errors 4, 285

doctrine of double effect (DDE) 81–82

documentation 94–95

Donoghue v Stevenson (1932) 50

‘do no harm’ 79–80

dosage(s)

children/young people 263

older people 260

renal impairment 247, 248, 249–250

dosage form 152

dose–response ‘ceiling’ effect 167

doxazosin 170

drug classification 37, 38

drug companies, influence on prescribing 105–107, 199

drug costs, NHS 7, 105, 177, 199, 296

cost-effective prescribing 103, 174, 294, 298

drug-dependency 61

drug history (DH) 130–131

drug–illness interactions 167

drug interactions

examples 164, 171, 244
management and avoidance 167–169
narrow therapeutic index drugs 175
oral contraceptives 244
pharmacodynamic 167
pharmacokinetic 168
polypharmacy 167, 171
protein-bound drugs 153
drug promotion 106
drug–protein complex 153, 244
Duloxetine 164–165
duty of care 50–52, 78, 97
breaches 50
dyspnoea 208–209
Dysport® 44

ear, nose and throat system see ENT system
ears, examination 218–219, 219
EASE mnemonic xvi
economics and funding 7–8, 92–93, 298
cost savings of non-medical prescribing 284, 298
CPD 95–96
drug costs see drug costs, NHS
local formularies 104
long-term conditions and 149
R&D costs 106
see also cost-effectiveness
education/education programmes 4
access to 27–29
adverse drug reactions 174
ageing workforce 286
allied health professionals 29
consent 66
criteria for access 28
to diagnose 280
inadequacy of courses 36
independent prescribing 13
infrastructures 287
MDPTS 188, 200, 201
NPC prescribing pyramid 58–59
nurses 19, 20, 21, 28, 286
optometrists 26, 29, 192
other countries 280
patient/family, specific drugs 164–165
pharmacists 29, 188
standards 28
supplementary prescribing 17
uptake of courses 278
V100 19, 20, 21

V150 21, 286
V300 21–22, 286
efficacy, non-medical prescribing 4–5
ego states 125
E-Learning for Health Care (2014) 5
elimination of drugs see excretion of drugs
emergency supply requests 54
employers, vicarious liability 41–42
employment contracts 42
end-of-life care 73, 81–82
enterohepatic circulation 244
ENT system 206
examination 218–220, 219, 220
enzyme(s) 156–160, 244
effects of drug action 161–162
induction/inhibition 154, 175
epilepsy 58, 251, 253
EQUIP study 236
errors 4
dispensing 76
medication 76, 178, 235
numeracy skills 285
prescribing see prescribing errors
erthromycin 170, 171
estimated glomerular filtration rate (eGFR) 247
ethics 35–88, 77–82
autonomy 60, 79
‘best interest’ see ‘best interest’ decision/principle
components 77
confidentiality 74
consent 64–65
definition 77
dilemmas 78
doctrine of double effect 81–82
drug companies 106
group/personal 77, 78
philosophical 77, 78
principles 79–80
professional 78
respect for persons 80
theories 78–79
virtue 79
withdrawal of consent 64–65
ethinylestradiol 244
ethnic factors/ethnicity 99, 100, 172
ethnic groups 269–271
European Convention of Human Rights and Biomedicine (1997) 64, 65
European Law 48
evidence-based practice 42–43, 96, 98, 104
evidence-based resources, CPD  295
excipients  265, 265
excretion of drugs  155, 166, 247
  breastfeeding and  256
  children/young people  263
  liver disease  244
  older people  258
  pregnancy  252
  renal impairment  166, 167, 171, 247, 249
expectations of patients  10–11, 97–98, 99, 107, 136
‘expressed need’  10
FACECARES mnemonic  176, 177
falls  261
families, involvement in MDPTs  194, 197
  family advocates  73
  Family Law Reform Act (1969)  69, 70
  family surrogates  73
fatalism  102
‘felt need’  10
fertility  254
fever  210
‘fifth vital sign’  214
first-pass metabolism/effect  153, 243
flucloxacillin  172
folic acid  254
follow-up  137
formularies  103–104
  building/developing  160–165
  Community Practitioner Nurse Prescriber  20, 162, 166
  impact on prescribing  103–104
  local  8, 104, 294
  nurse prescribers’  xiv, 20, 162
  nurse prescribers’ extended  xiv, 11, 22, 278
  personal  104, 160–165, 234, 253
  see also British National Formulary (BNF)
formulation of drugs, for children  264
Francis Report  36
‘Fraser competent’/guidelines  70–71
fraud  43
Freedom of Information Act (2000)  75
Freedom to Speak Up Review  43
friction rub  227
γ-aminobutyric acid (GABA), GABA receptors  158
gastric emptying  149, 150, 152, 262
gender, prescribing for  269
  adverse drug reactions  172
General Medical Council (GMC)  44, 62, 63, 236
General Optical Council (GOC)  26, 28, 192
General Pharmaceutical Council (GPhC)  2, 5, 23, 25, 28, 40, 188
  consent and  62
  shared decision-making  66
general sales list (GSL) medicines  37
generic medicines  174, 298
gentamicin  244, 248
‘Gillick competent’  70
Gillick v West Norfolk and Wisbech Area Health Authority (1985)  70
Glasgow coma scale (GCS)  206, 207, 207
  glomerular filtration rate (GFR)  247
glucose-6-phosphate dehydrogenase (G6PDH) deficiency  172
glucuronides  248
  good practice guidance  178, 237
  ‘good prescribing’  149, 178
governance  40
GPs, impact of non-medical prescribing on  282
gypsies  271
H2 receptor antagonists  158
  half-life of drugs  155–156, 156, 256
  harm, reducing  76–77
Health and Care Professions Council (HCPC)  2, 3, 24, 25, 28, 40
Health and Social Care Act (2001)  xiv
Health and Social Care Act (2008)  289
Health and Social Care Act (Regulated Activities) Regulations 2009  289
health beliefs  101
  models  101–102
  young people  267
Health Care and Associated Professions (Indemnity Arrangements) Order 2014  40–41
Healthcare Quality Improvement Partnership (HQIP)  293
Health Education England  4, 287
  health professional case studies  310–314
Health Professions Council (HPC)  191, 192, 193
  health promotion  10, 13, 90
  health psychology  101
health status
  black and minority ethnic groups  270, 270
  gypsies and travellers  271
  health visitors  xiv, 20, 22
  case study  310
  education programmes  22, 28
heart rate  212
hepatic encephalopathy 245–246
hepatotoxicity 171
heuristics 141–142
histamine H₂ receptor blockers 158
history (of non-medical prescribing) 1–2, 3, 277, 278, 278–280
history of presenting complaint (HPC) 128–129
history taking 126–135, 216
  aide memoire 127
  children 266–267
  elements in 127, 127, 128–134
  illustration 127, 128–134, 134
  pregnancy 253
  remote prescribing 44
HIV infection 172
holistic approach xv, 7, 11, 100
  BME groups 270
  breastfeeding 257
  children/young people 266–268
  in co-morbidity 166
  liver disease 246, 247
  MDPTs 194
  older people 260–261, 261
  pregnancy 254, 255
  renal impairment 250, 250
hospital admission, drug-related 178, 236, 258
hospital care see secondary (hospital) care
Human Rights Act (1998) 64, 75
hyoscine 170
hyperkalaemia 249
hypertension 160, 163, 164, 167, 168
  case studies 307, 308
  medicine management 177
hypnotics 245, 259
hypothetical–deductive model 139–140, 141, 144
hypoxia 209
idiosyncratic reactions 171
immunisation 27, 108
impact of prescribing 281–284
  on doctors 282
  organisational 283–284
  on patients 282–283
  on prescribers 281–282
impression, in history taking 134
indapamide 163, 167
independent prescribers, definition 14
independent prescribing xiv, 6, 12–14
  allied health professionals 190
  assessment 12–14
case studies 24, 25
clinical decision-making 13–14
controlled drugs 53
  definition 12, 14, 22
education 13
factors preventing/limiting 283–284
health professional requirements 14
increase in 18
MDPTs 189, 190, 191, 192
nurses 53, 90
optometrists 26, 53, 192
pharmacists 23, 24, 53, 189
physiotherapists 25, 191
podiatrists 25, 193
radiographers 191–192
supplementary prescribing vs 11–19
undiagnosed conditions 12, 13
V300 and 21–22
infection, detecting/monitoring for 210, 213
information
  access, for patient safety 94, 96–97
  disclosure 65, 74
  for informed consent 66
  MDPTs 186
  patient expectations based on 98
  from pharmaceutical companies 106
  sharing 74–75, 186
informed consent 63–66
injectable medicines 9, 44–45
inspection 217
  abdomen 227
  respiratory system 223
insurance, professional indemnity 40–41
interdisciplinary work see multidisciplinary prescribing teams (MDPTs)
international normalised ratio (INR) 242, 245
Internet 107
intuition 141–142, 143
  definitions 142, 142
ion channels 157, 158–159, 161
isolation of prescribers 92
Jehovah’s Witness 71
job satisfaction 4, 281
‘joint vicarious liability’ 42
junior doctors 4, 6
justice, principle of 80
Kant, Immanuel 60, 66, 78
Kent and Medway Strategic Health Authority 287–288
knowledge
patients’ and consent 66
patients’ and expectations 98
prescribers’ 51, 60, 76, 91, 98
Knowledge and Skills Framework (KSF) 291
Kurtz’s Enhanced Calgary-Cambridge Guide 116, 125, 126
lactation difficulties 257
languages 100, 270
lasting power of attorney (LPA) 67, 71–72, 80
Latin abbreviations 55, 56, 57
legal issues and legislation 35–88, 206
autonomy and consent see autonomy; consent
avoiding litigation 76, 76–77
doctrine of double effect 81–82
framework changes for prescribing 36, 37, 47
law types 48–49, 49
negligence and duty of care 50–52
other countries 35, 280
prescription writing 52–53
primary/secondary legislation 48
professional regulations 37
UK laws 47–48
UK legal system 47–77
unlicensed/’off-label’/’off-licence’ medicines 53–54
licensing of medicines 264
lidocaine 159
life-saving treatment, consent and 70, 71
ligand 156
ligand-gated ion channels 157, 158
lipid-soluble drugs 155, 167, 251, 258, 262
listening 117, 126
Lister and ors v Hesley Hall Ltd (2001) 41
lithium 155, 168, 174, 175, 256
litigation 236
avoiding 76, 76–77
liver disease/impairment, prescribing in 165, 166, 171, 241–247
adverse drug reactions 171
diagnosis 243
holistic approach 246, 247
pharmacology 243–246
signs and symptoms 242, 242
liver function
drug metabolism 154, 165–166, 244
tests 242, 242, 246
‘living wills’ 72
local anaesthetics 159, 193
local counter-fraud specialist (LCFS) 46
location of prescribing consultation 92
locus of control theory 102
‘lone workers’ 92
long-term conditions 122, 149, 246
gypsies and travellers 271
polypharmacy 166–167
psychological needs of patients 246
supplementary prescribing 17–18
lymph node examination 222
Macmillan nurses 286, 287
management plan see clinical management plan (CMP)
management responsibilities 92
marketing authorisation (MA) 264
marketing campaigns 106
MDPT see multidisciplinary prescribing teams (MDPTs)
media influence on prescribing 107–108
Medical Defence Union (MDU) 41, 76
Medical Devices Agency (MDA) 38
medic alert bracelets 207
medical ethics see ethics
medical litigation 50
medical prescribing, non-medical prescribing
vs 4–5, 190, 279–280, 282
medication appropriateness index (MAI) 280
medication errors 76, 178, 235
medication review 235–237, 260
medicine interactions see drug interactions
medicine optimisation 42–43
Medicines Act (1968) 37, 52, 105
Medicines Act (1971) 38
Medicines Act (1992) 1–2
Medicines and Healthcare Products Regulatory Agency (MHRA) 9, 37, 152
advertising of drugs, control 105
drug promotion breaches 105
marketing authorisation 264
responsibilities 38
unlicensed medicines 152
Yellow Card Scheme 38, 173
Medicines Control Agency (MCA) 38
medicines management 149, 177–178, 298
medicines optimisation 178, 235, 236
principles 236, 236–237
men, prescribing for 269
mens rea 49
mental capacity 68–69
adults lacking 61, 65, 67–69, 71–72
assessment 58, 68–69
children 70
consent 61, 62–66, 70
DH guidance 67–68
Fraser competence 70
last ing power of attorney 71–72
temporary lack of 68
mental health/illness 166, 261
black/minority ethnic groups 270–271
impact of non-medical prescribing 283
you ng people 267
mental health nurses, lack of prescription writing 286
mentoring 93, 297
metabolism of drugs 154, 165, 166
children/young people 263
ethnicity and 172
liver impairment and 165, 166, 171
older people 258
pregnancy 252
renal impairment 248–249
metabolites 155, 244, 248–249
metric system 235
Mid Staffordshire NHS Foundation Trust 36
midwives 22, 266
accountability and responsibility 40
case study 22, 311
education programmes 28
MDPTs 189–190
professional code of practice 39, 39
supplementary prescribing 17, 21–22
V300 prescribing 21–22, 28
migrants 100
minority groups 269–271
Misuse of Drugs Act (1971) 37–38, 38, 58
Misuse of Drugs Regulations (2001) 58
Misuse of Drugs Regulations (2012) 280
mixing of medicines 152
Modernising Nursing Careers (DH 2006) 186
modification of diet in renal disease (MDRD) 247
‘moral rule’ 47
‘morals’ see ethics
morbidity, in UK 166
mouth examination 221
multidisciplinary prescribing teams (MDPTs) 93, 183–204
allied health professional role 190
barriers/challenges 108, 186–187, 201
benefits 108, 185–188, 196–197, 201
case study 199, 313
chemotherapy prescribing 196
‘close communication’ 108
commissioning 197–199
communication skills 198
‘contact’ professional 199
CPD 186–187
definition 183–185
drivers in/for 184–185, 195, 195
dynamics 4
education 188, 200, 201
ethos 185–186, 187
goals 200
health service structures 187
holistic approach 194
influence on prescribing 108–109
information sharing 186
lead person 194, 197, 199
model for working practice 185–187
non-medical 187–188, 188, 194–197
non-medical prescribing lead 194, 279, 287, 292
nurse/midwife prescriber roles 189–190
organisation 185, 185–186
patient involvement 194, 195, 195
pharmacist prescriber roles 188–189
physiotherapists 191
podiatrists 192–193
problems with 198–199
radiographers 191–192
role of members 186, 188–193, 194, 198–199
team members 194, 198, 201
terminology confusion 184
mumps, measles and rubella (MMR) immunisation 108
narrow therapeutic range 154, 166, 174–177
renal impairment and 247
National Audit Office (NAO) 298
National Clinical Governance Support Team 288
national health targets 11
National Institute for Health and Clinical Excellence (NICE) 42–43, 102–103, 176, 289
medicines optimisation 235
psychological needs of patients 246
renal impairment 247
National Patients Safety Agency (NPSA) 4
National Prescribing Centre (NPC) xv, 3, 54, 58
National Service Frameworks (NSFs) 257, 260, 267, 289
neck examination 222
needs of patients 10–11
negligence 50–52
  claims for 51
negotiation, management plan 117, 136
Neighbour’s Inner Consultation 116, 125–126
neonates 256, 262, 263
neostigmine 160
nephrotoxicity 171, 249
neural tube defects 254
neurological examination 229–232
New Consultation model (Pendelton) 116, 125, 126
New Zealand 281
NHS
  drug costs 105, 177, 199
  history of prescribing and 278–279
  staff and staff structures 187
  whistleblowing 43
NHBSA Prescription Services 279
NHS Business Services Authority 46
NHS Constitution 36, 178
The NHS Plan (DH 2000) xiv, 277, 290
NHS Redress Act 2006 51, 52
NHS Redress Bill (2005) 51
NHS Redress Scheme 52
nicotine 156–157
non-adherence 98
non-compliance 175, 176, 268
non-maleficence 79–80
non-medical prescriber database 291
non-medical prescribing see prescribing (non-medical)
non-medical prescribing forums 292
non-medical prescribing lead 194, 279, 287, 292
non-steroidal anti-inflammatory drugs (NSAIDs) 155, 167, 171, 249, 259
non-verbal communication 117, 119, 120
noradrenaline (NA) 159, 164
‘normative needs’ 10, 11
nose and sinus examination 220
notification of GPs 95
numeracy 232, 234–235
  assessment 285
  errors/problems 235, 285
  metric system 235
  skills required 234
Nurse Prescribing Bulletin (NPC 1999) 3
nurse prescribing/prescribers xiv, 1–2, 19–23
  accountability and responsibility 40
  ageing workforce 286–287
case studies 311
CPD see continuing professional development (CPD)
education programmes 19, 20, 21, 28, 286
extended formulary xiv, 11, 22, 278
failure to prescribe 190, 279, 286, 291
formularies xiv, 20, 162
history 1–2, 3, 277–278
impact of prescribing on 281–282
impact on patients 282–283
independent prescribing xiv, 8–9, 53, 90
influences in prescribing 90, 91, 281
MDPTs 189–190
negligence and duty of care 51
number 278, 279
other countries 280–281
percent of prescriptions 90
professional code of practice 39, 39
professional regulation 189
responsibilities and competencies 190
supplementary prescribing 284
unlicensed medicines 53–54
V100 19, 20, 21, 28
V150 19, 21, 28, 286
V200 22
V300 19, 21–22, 28, 286
‘nursing,’ definition 22
Nursing and Midwifery Council (NMC) 3, 9, 28, 40, 189
  informed consent and 66
  prescribing for children 266
  remote prescribing 44
  transcribing 45
unlicensed medicine prescribing 54
off-label medicines 53–54, 264
off-licence medicines 53–54, 264
older people 257–262
  adverse drug reactions 171, 172
  autonomy 59
  case studies 305, 306
  co-morbidity and polypharmacy 166–167
  consultations 122, 124
  drugs to be used with caution 259
  holistic approach to prescribing 260–261, 261
  liver function 171
  narrow therapeutic index drugs 175
  pain assessment 215
  pharmacodynamics 259
  pharmacokinetics 258
  polypharmacy 166–167, 257
  prescribing considerations 260, 261
renal function 171, 247–248
opiates 81, 82, 170, 245
optometrists 26
case study 314
education programmes 26, 29, 192
independent prescribing 53, 192
MDPTs 192
oral contraceptives 244, 254
organisational culture 93
organisational issues, prescribing process 93, 94–95, 287
impact of non-medical prescribing 279, 283–284
organisational responsibilities 137
organisations, CGC standards and regulations 289
orthopnoea 208–209
orthotics 193
over-the-counter medications 99
PACT data 292, 293–294
pain
assessment 214–216
prescribing for 214, 215–216
palliative care 170, 287
palpation 217
abdomen 228
respiratory system 223
paracetamol 169–170
paramedics 280
parenteral formulations, breastfeeding and 256
parents 70, 267, 268
orthopnoea 208–209
partnership 15, 17, 292
past medical history 130
past surgical history 130
paternalism 59
patient(s)
acceptability of products 103
acceptance of non-medical prescribing 4
autonomy see autonomy
awareness of health behaviour 102
case studies 305–309
concordance and 176
confidentiality 74–75
consultations 96–97, 98
as consumers 98–99
as consumers 98–99
cultural issues 99–101
disclosure 74
disclosure 74
empowerment 102
expectations 10–11, 97–98, 99, 107, 136
as consumers 98–99
as consumers 98–99
harm, prescribing errors 285
health beliefs 101–102
impact of non-medical prescribing on 282–283
influence on prescribing 96–102
information, accessibility/confidentiality 74–75, 75
involvement in decision-making 117
involvement in MDPTs 194, 195, 195–196
knowledge influence on expectations 98
language differences 100
MDPT benefits for 195–197
monitoring after prescribing 205
participation and informed consent 66
perception of pharmacists 189
prescriber relationship see prescriber/patient relationship
as priority 113, 114
safety see safety
satisfaction with non-medical prescribing 282–283
spirituality and religion 100–101
patient group directions (PGDs) 25, 26–27, 52
definition 26
indications for 26, 27
prescribing differences 26, 37
radiographers 191
pattern recognition 140–141, 143, 144
peak expiratory flow rate (PEFR) 209, 210
Pendleton’s New Consultation model 116, 125, 126
percussion 217
abdomen 228
notes/sounds 225
respiratory system 223
paracetamol 169–170
paramedics 280
parenteral formulations, breastfeeding and 256
parents 70, 267, 268
paroxysmal nocturnal dyspnoea (PND) 208–209
partnership 15, 17, 292
past medical history 130
past surgical history 130
paternalism 59
patient(s)
acceptability of products 103
acceptance of non-medical prescribing 4
autonomy see autonomy
awareness of health behaviour 102
case studies 305–309
concordance and 176
confidentiality 74–75
consultations 96–97, 98
as consumers 98–99
as consumers 98–99
cultural issues 99–101
disclosure 74
disclosure 74
empowerment 102
expectations 10–11, 97–98, 99, 107, 136
as consumers 98–99
as consumers 98–99
harm, prescribing errors 285
health beliefs 101–102
impact of non-medical prescribing on 282–283
influence on prescribing 96–102
information, accessibility/confidentiality 74–75, 75
involvement in decision-making 117
involvement in MDPTs 194, 195, 195–196
knowledge influence on expectations 98
language differences 100
MDPT benefits for 195–197
monitoring after prescribing 205
participation and informed consent 66
perception of pharmacists 189
prescriber relationship see prescriber/patient relationship
as priority 113, 114
safety see safety
satisfaction with non-medical prescribing 282–283
spirituality and religion 100–101
patient group directions (PGDs) 25, 26–27, 52
definition 26
indications for 26, 27
prescribing differences 26, 37
radiographers 191
pattern recognition 140–141, 143, 144
peak expiratory flow rate (PEFR) 209, 210
Pendleton’s New Consultation model 116, 125, 126
percussion 217
abdomen 228
notes/sounds 225
respiratory system 223
paracetamol 169–170
paramedics 280
parenteral formulations, breastfeeding and 256
parents 70, 267, 268
paroxysmal nocturnal dyspnoea (PND) 208–209
partnership 15, 17, 292
past medical history 130
past surgical history 130
paternalism 59
patient(s)
acceptability of products 103
acceptance of non-medical prescribing 4
autonomy see autonomy
awareness of health behaviour 102
case studies 305–309
concordance and 176
confidentiality 74–75
consultations 96–97, 98
as consumers 98–99
as consumers 98–99
cultural issues 99–101
disclosure 74
disclosure 74
empowerment 102
expectations 10–11, 97–98, 99, 107, 136
as consumers 98–99
as consumers 98–99
harm, prescribing errors 285
health beliefs 101–102
impact of non-medical prescribing on 282–283
influence on prescribing 96–102
information, accessibility/confidentiality 74–75, 75
involvement in decision-making 117
involvement in MDPTs 194, 195, 195–196
knowledge influence on expectations 98
language differences 100
MDPT benefits for 195–197
monitoring after prescribing 205
participation and informed consent 66
perception of pharmacists 189
prescriber relationship see prescriber/patient relationship
as priority 113, 114
safety see safety
satisfaction with non-medical prescribing 282–283
spirituality and religion 100–101
patient group directions (PGDs) 25, 26–27, 52
definition 26
indications for 26, 27
prescribing differences 26, 37
radiographers 191
pattern recognition 140–141, 143, 144
peak expiratory flow rate (PEFR) 209, 210
Pendleton’s New Consultation model 116, 125, 126
percussion 217
abdomen 228
notes/sounds 225
respiratory system 223
paracetamol 169–170
paramedics 280
parenteral formulations, breastfeeding and 256
parents 70, 267, 268
paroxysmal nocturnal dyspnoea (PND) 208–209
partnership 15, 17, 292
past medical history 130
past surgical history 130
paternalism 59
patient(s)
acceptability of products 103
acceptance of non-medical prescribing 4
autonomy see autonomy
awareness of health behaviour 102
case studies 305–309
concordance and 176
confidentiality 74–75
consultations 96–97, 98
as consumers 98–99
as consumers 98–99
cultural issues 99–101
disclosure 74
disclosure 74
empowerment 102
expectations 10–11, 97–98, 99, 107, 136
as consumers 98–99
as consumers 98–99
harm, prescribing errors 285
health beliefs 101–102

Index

pharmacists/pharmacist prescribers (cont’d)
education programmes 29, 188
employment and roles 189
impact of prescribing on 90, 91, 282
implementation of prescribing 91
independent prescribing 8–9, 23, 24, 53, 189
influence on prescribing 90, 91, 190
in MDPTs, role 188–189
monitoring of patients 90
negligence and duty of care 51
number 279
prescribing error detection 285
professional code of practice 39, 39
professional regulation 28, 53, 188
public perception of 189
remuneration 92–93
supplementary prescribing 23–24, 189, 282
training 188
unlicensed medicines 53–54, 152
pharmacodynamics 150, 156–160, 161–162
antihypertensives 163
cor-morbidity 166
diabetic neuropathy management 164
impact on patient care 150
in liver disease 244, 245–246
medicine interaction 166
older people 259
renal impairment 249–250
pharmacokinetics 149–150, 151–156
antihypertensives 163
children/young people 262–265
cor-morbidity 165, 166
diabetic neuropathy management 164
drug interactions 168
impact on patient care 149–150
in liver disease 243–244
older people 258
in pregnancy 251–252, 252
renal impairment 248–249
pharmacology 149–150
formularies and 162–163
in liver disease 243–246
prescribing in co-morbidity 165–167
terms used in 150–160
pharmacovigilance 99, 173
pharmacy (P) medicines 37
pharynx, examination 221
phenobarbital sodium 58
phenytoin 168, 169, 248
physical examination see clinical examination
physiotherapists xiv
case study 313
independent prescribing 25, 191
MDPTs 191
supplementary prescribing 18, 24–25, 313
podiatrists xiv
case study 314
for children 193
independent prescribing 25, 193
MDPTs 192–193
supplementary prescribing 19, 24–25
training 192–193
podopaediatrics 193
polypharmacy 166–167, 257
adverse drug reactions 171–172
case studies 307
PQRST mnemonic 214
practitioners, use of term 113
precedent 47
pregnancy 251–255
case study 306, 307
holistic approach to prescribing 254, 255
information sources 252–253
pharmacokinetics 251–252, 252
physiological changes affecting drugs 251, 252
prescribing considerations 255
prescribing principles 252–253
prejudices 271
premature infants 256
prescriber(s)
accountability and responsibility 40, 117
as advocates 72–73
aims for (‘good prescribing’) 178
attributes, therapeutic communication
and 117
confidence 104
impact of prescribing on 281–282
influence on prescribing 89–96, 281–282
infrastructure for 287
institutional/resource factors
influencing 92–94
intention to prescribe 291
maintaining ‘own’ person 126
non-medical/medical relationships 93, 138
notification of GPs of prescription 95
numbers 278
personal characteristics 91, 119, 121
pharmaceutical company relationships 106
responsibilities 137
role/responsibility changes 92–93
vulnerability 92
prescriber/patient relationship
consent 64, 65
consultation 97, 98, 115, 117
consultation models 124, 125
culture 99–101
development 119–122
disclosure of information 74
ethical principles and consent 64–65
health beliefs 101
importance 119
paternalism and 59
patient expectations and 97, 98
prescribing (non-medical) 1, 148
ambivalence and success 91
benefits 3, 4, 13, 89–90, 185–188, 283
challenges 94–95, 206
concerns/objections/criticisms 4, 206
consultation time 94–95, 97
controlled drugs 58
culture influencing 99–101
debate over 278–280
definition 2, 45, 51
development xiii–xiv, 277
drug companies influencing 105–107, 199
‘dumbing down’ 279
expansion/extension (roles) 6, 278, 279
external influences 105–110
factors influencing practice of 5, 89–112
history 1–2, 3, 277, 278, 278–280
increase in 3–4, 90, 278, 284
local barriers 93
medical prescribing relationship 4–5, 190, 279–280, 282
organisational issues 93, 94–95
other countries 280–281
patient influences on 96–102
PGDs differences 26, 37
policy, strategies 291–293
prescribers influencing success 89–96
pressures and responses 29, 29–30, 92–93
principles see prescribing principles
priorities, and role 6
product choice influencing 102–103
professional issues influencing 95–96
unethical 106
prescribing budget 7
prescribing errors 4, 55, 76, 285
avoiding litigation 76
MDPTs and 198
numeracy skills 235
pharmacists recording 189
rate 236
transcribing 46
prescribing principles xv, xv–xvii, 1–2, 3, 6, 7, 55
key principles 3, 3
of pregnancy 252
stepwise approach xv, xvi
summaries/considerations 30, 83, 109, 145, 179, 202, 238–239, 272, 298
prescribing pyramid 58
prescribing rights 53
abuse 43, 60
prescription(s)
dangers of abbreviation use 55–56
dosage calculation 234
errors 55
number 279, 285
nurses not writing 190, 279, 286, 287, 291
percent written by nurses 90
spending on 7, 105, 177, 296
time required to generate 94–95
Prescription Cost Analysis for England 2012 7
prescription forms 46
prescription-only medicine (POM) 37–38, 58
Prescription Only Medicine Orders 1997 37, 58
Prescription Only Medicines (Human Use) Order 1997 38
prescription writing 52–53, 55, 95
decision to write 136
guidelines 56
lack after qualification 190, 279, 286, 287, 291
‘what strategy’ 54–55
prescribing complaint 128, 134
pressures on prescribing 29, 29–30
primary care, prescribing agreements 93
primary care trusts (PCTs) 284, 298
principle of double effect (PDE) 82
principlism 79–80
private law 48, 49
private sector 8–9
problem-oriented medical record (POMR) 127
product influence on prescribing 102–104
choice 102–103
formularies 103–104
professional ethics 78
professional framework 36–46, 37
professional indemnity 40–41
professional integrity 80
professional issues influencing prescribing 95–96
professional misconduct 43
professional standards of conduct 39, 39
proprietary name prescribing 174–175
prostaglandins 155
protein binding 153–154, 244, 248, 256
psychological needs of patients 246
Public Concern at Work (PCAW) 43
public health 9–10
policy (UK) 9–10
summary/considerations 30, 83, 109, 144, 179, 202, 238–239, 272, 298
Public Health England 100, 269
Public Health Outcomes Framework indicators 10
public law 48, 49
pulse 211
pulse oximetry 209, 209
pulse rate 211–213
abnormal findings 212
age 212
pyrexia 210, 211
quality 288, 290
quality-of-life 80
radial artery, pulse 211
radiographers
case study 313
diagnostic 191–192
independent prescribers 191–192
MDPTs 191–192
supplementary prescribing 24–25, 313
therapeutic 191–192
training 191
ramipril 165
receptors 150, 156–160, 157
examples of drug action 161
recompense, negligence claims 51
records
access to 19, 75, 96
avoiding litigation 76, 77
confidentiality 74, 75
consent 63
keeping, principle xvii
supplementary prescribing 16, 19
transcribing and transposing 45–46
rectal temperature monitoring 210
red flags 217, 218
Re E (1993) 71
referral procedures 136–137
reflective practice 297
reflexes 229, 233
grading 234
reinforcement 229
refusal of treatment 58
regulatory framework 36–46, 37
religion 100–101
’remedy’ (legal) 51
remote prescribing 13, 44–45
remuneration 92–93
renal blood flow 155
renal function
adverse drug reactions and 171
age-related decline 166, 167, 258
assessment 247–248
children 262
excretion of drugs 155, 166, 171, 247
older people 247–248
see also excretion of drugs
renal impairment, prescribing in 166, 167, 171, 247–251
holistic approach 250, 250
pharmacodynamics 249–250
pharmacokinetics 248–249
repeat prescriptions 94–95
repetition of tasks 95
representativeness 140
research and development costs 106
respect for autonomy 79
respect for persons 80
respiratory rate 207–210
respiratory system 207–210
age 207–209
examination 220–221, 223–224
peak flow 209, 210
pulse oximetry 209, 209
responsibility 40, 42, 51, 96, 190
care for children 266
changes for prescribers 92–93, 96
increased, impact on prescribers 281–282
prescribers, consultations 137
review of systems (ROS) 133–134
risk assessment 76–77
risk management 76–77
Royal Sussex Hospital 43
rule of double effect (RDE) 82
R v Cox (1957) 82
R v Moor (2000) 82
Rx (prescription) 57
safeguarding 268
safety 4–5, 29, 113, 114, 148
access to information for 94, 96–97
agencies/organisations 5
children 256, 264, 266
clinical decision-making 141
impact of prescribing 282
Neighbour’s Inner Consultation model 125
numeracy skills and 235
pregnancy 252–253
prescriber virtues 36
prescription forms 46
product choice and 104
therapeutic communication enhancing 117
St John’s wort 169
salbutamol 150
Salmond test 41
Saving Lives: Our Healthier Nation (DH 1999) 13
school nurses, consent 20
scope of practice statement 291
secondary (hospital) care 6, 122, 214, 298
prescribing agreements 93
prescriptions 294
secondary legislation 48, 51
self-awareness of cultural beliefs 100
self-medication 98–99
self-monitoring, by men 269
sharing of information 74–75
Shipman, Harold 43, 60
Sidaway v Bethlem Royal Hospital Governors (1985) 64, 65
side effects 170
adverse drug reactions vs 170
consent and 64
doctrine of double effect and 82
duloxetine 164, 165
information for patients 165
management 170
see also adverse drug reactions (ADRs)
signs and symptoms 216
silence 118
simvastatin 171
Single Competency Framework (NPC 2012) xvii, 13, 296, 297
sinuses, examination 220
social and cultural issues 101–102
black/minority ethnic groups 269–270
summary/considerations 30, 83, 109, 144, 179, 202, 238–239, 272, 298
see also culture
Social Care Institute for Excellence (SCIE) 289
social history (SH) 131–133
‘social rule’ 47
sodium ion influx 159
‘specials’ 264
specificity 156
sphygmomanometers 213
spirituality 100–101
standard operating procedures 292
standards of conduct, professional 39, 39
statutes 47, 48, 88
sulphasalazine 172
summaries of product characteristics (SPCs) 162, 243, 253
summarising, consultation model 125
summary, consultation model 134
supervision 292, 297
supplementary prescribing xiv, 14–19
allied health professionals 190
benefits 18, 23
case study 23–24
CMPs see clinical management plan (CMP)
consent 63, 71
definition 14–15
DH guidelines 291
diagnosis responsibility and 19
factors preventing/limiting 284
health professionals undertaking 17
independent prescribing vs 11–19
limitations/concerns 18–19
long-term conditions 17–18
nurse prescribing 284
optometrists 26, 192
partnership principle 15, 17
pattern recognition 140
pharmacists 23–24, 189, 282
pharmacokinetics and 152
physiotherapists 18, 24–25, 313
podiatrists 19, 24–25
radiographers 24–25, 313
resistance to 17–19
termination 17, 17
support for prescribers 92, 93, 287–288
support forums 287, 288
Sweden 281
symptom analysis tools 135
systolic pressure 213
tachycardia 212
tachypnoea 208
tacit knowledge 142
targets of drug action 156–157, 157, 161–162
teams see multidisciplinary prescribing teams (MDPTs)
technology, access to printing 95
teenagers see children and young people
telephone prescribing 44
temperature (body) 210–211
guidelines for monitoring 211, 211
temple model (pillars of clinical governance) 288
teratogenicity and teratogens 251
tests and investigations 136
thalidomide 38, 251
theophylline 174, 175
theory of reasoned action 101–102
therapeutic communication 114, 115–124
children and young people 122, 267
clinical decision-making 139, 141
consultation 114, 127, 139
definition 117
enhancing, considerations 122
history taking 127, 139
older people 122
paralinguistic features 117, 118
relationship development 119–122
value 115–124
verbal and non-verbal 117, 118, 119
therapeutic drug monitoring (TDM) 174
therapeutic range, narrow see narrow therapeutic range
thiazide-like diuretics 163
time
consultations 94–95, 97
listening to patients, history taking 126
for prescribing 94–95, 97
tobacco smoking 157–158, 175
tolcapone 171
tort law 50
touch 120
transcribing 45–46
errors 46
transposing 45–46
travellers 271
‘trespass to the person’ 61
tricyclic antidepressants 159, 170, 245, 259
trust 93, 97, 186
tuberculosis 171
tympanic membrane, examination 218–219, 219
tympanic membrane temperature 210, 211
undiagnosed conditions, independent prescribing 12, 13
unlicensed medicines 53–54, 152
allied health professionals 25
for children 264
nurses 152
pharmacists 23, 24, 152
supplementary prescribing 25
unwanted effects of drugs 169–170
see also adverse drug reactions (ADRs)
USA 280, 281
utilitarianism 78
V100 prescribing xiv, 19, 20, 21, 28
V150 prescribing 21, 28, 286
V200 nurse prescribers 22
V300 prescribing 21–22, 28, 286
verbal communication 117, 118
vicarious liability 41–42
virtue ethics 79
Vistabel® 9, 44
vital signs 206, 237
additional 214–216
voltage-gated channels 159
voltage-sensitive ion channels 157, 158
vulnerability in society 184
vulnerability of prescribers 92
warfarin 154, 259
wastage of medicines 178, 284, 298
water-soluble drugs 244, 248, 249
‘welfare guardian’ 72
whistleblowing 43
withholding of information 59
workload 95
writing prescriptions see prescription writing
written consent 63
Yellow Card scheme 38, 173
‘yellow flags’ 218
young people see children and young people